245 related articles for article (PubMed ID: 29490321)
21. Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.
Ozakbas S; Piri Cinar B; Baba C; Kosehasanogullari G; Sclerosis Research Group M
Acta Neurol Scand; 2022 May; 145(5):557-564. PubMed ID: 35043388
[TBL] [Abstract][Full Text] [Related]
22. Childhood multiple sclerosis: clinical features and recent developments on treatment choices and outcomes.
An Q; Fan CH; Xu SM
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5747-5754. PubMed ID: 30229853
[TBL] [Abstract][Full Text] [Related]
23. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani MP; Muraro PA; Saccardi R; Mancardi G
Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454
[TBL] [Abstract][Full Text] [Related]
24. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R
Curr Med Res Opin; 2018 Aug; 34(8):1419-1430. PubMed ID: 29583054
[TBL] [Abstract][Full Text] [Related]
25. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
26. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
27. Correlation of selected serum protein levels with the degree of disability and NEDA-3 status in multiple sclerosis phenotypes.
Lamancová P; Urban P; Mašlanková J; Rabajdová M; Mareková M
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3933-3941. PubMed ID: 35731063
[TBL] [Abstract][Full Text] [Related]
28. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
30. Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials.
Bayas A; Christ M; Faissner S; Klehmet J; Pul R; Skripuletz T; Meuth SG
Ther Adv Neurol Disord; 2023; 16():17562864221146836. PubMed ID: 36710720
[TBL] [Abstract][Full Text] [Related]
31. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
[TBL] [Abstract][Full Text] [Related]
32. Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment.
Zanghì A; D'Amico E; Patti F
Expert Rev Neurother; 2020 Aug; 20(8):771-782. PubMed ID: 31971026
[TBL] [Abstract][Full Text] [Related]
33. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
34. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
Prosperini L; Fanelli F; Pozzilli C
J Neurol Sci; 2016 May; 364():145-7. PubMed ID: 27084235
[TBL] [Abstract][Full Text] [Related]
35. The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.
O'Loughlin E; Hourihan S; Chataway J; Playford ED; Riazi A
Disabil Rehabil; 2017 Sep; 39(18):1821-1828. PubMed ID: 27685028
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.
Craddock J; Markovic-Plese S
Expert Rev Clin Pharmacol; 2015 May; 8(3):283-96. PubMed ID: 25916665
[TBL] [Abstract][Full Text] [Related]
37. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.
Gakis G; Angelopoulos I; Panagoulias I; Mouzaki A
Autoimmun Rev; 2024 Feb; 23(2):103480. PubMed ID: 38008300
[TBL] [Abstract][Full Text] [Related]
38. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
